Form 4: Alkermes EVP Blair C. Jackson Reports Stock Transactions

Blair C. Jackson, EVP and Chief Operating Officer of Alkermes plc, reports the acquisition and disposal of ordinary shares and derivative securities.

Summary

• On February 18, 2025, Blair C. Jackson, EVP and Chief Operating Officer of Alkermes plc, reported transactions involving Alkermes ordinary shares.
• Jackson acquired 8,896 shares through the vesting of restricted stock units.
• Jackson disposed of 3,950 shares to cover tax obligations at a price of $35.9 per share.
• Following these transactions, Jackson directly owns 186,494 ordinary shares.
• On February 19, 2025, Jackson acquired 77,565 shares through employee stock options with an exercise price of $35.84, which vest in four equal annual installments commencing on February 19, 2026, and expire on February 19, 2035.
• Jackson also acquired 37,203 shares through restricted stock unit awards, which vest in four equal annual installments commencing on February 19, 2026.
• Following these transactions, Jackson directly owns 8,897 restricted stock unit awards, 77,565 employee stock options, and 37,203 restricted stock unit awards.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine transactions related to executive compensation. There's no indication of unusual activity or significant concern.

Positives

• The acquisition of shares through vesting of restricted stock units and employee stock options indicates confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces Jackson's direct holdings.

Risks

• The value of the acquired shares is subject to market fluctuations, which could impact the overall value of Jackson's holdings.
• The vesting of stock options and restricted stock units is contingent upon continued employment, creating a potential risk if Jackson were to leave the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest a continued commitment from the executive to the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices in the pharmaceutical industry, used to align management's interests with those of shareholders.
• Vesting schedules of four years are fairly standard in the industry, encouraging long-term commitment.
• Comparing the size of the grants and the exercise price to those of peer companies like Biogen, Vertex Pharmaceuticals, and Regeneron would provide a more comprehensive assessment of the competitiveness of Alkermes' executive compensation.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
• The vesting schedules incentivize the executive to remain with the company, potentially benefiting employees and other stakeholders.

Key Dates

Keywords

Alkermes, Jackson, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership, Insider Trading